Skip to main content

Table 5 Hematologic and cytogenetic analyses

From: Patan hospital experience in treating philadelphia chromosome/BCR-ABL1 positive chronic myeloid leukemia patients with gleevec (imatinib mesylate); the first generation specific tyrosine kinase inhibitor

Hematologic Analysis

Cytogenetic Analysis

Total patients

106

 

Complete

20

68.97%

Excluded

3

 

Partial

6

20.69%

Total Patients Eligible

103

100%

Major

26

89.66%

CHR at Presentation

15

15%

Minor

2

6.89%

CHR in <3 months

81

78%

Minimal

1

3.45%

CHR in >3 months

7

7%

Total

29

 
  1. CHR: complete hematologic response